797784-29-3

Basic information

• Product Name: 2-(3,5-DIFLUOROPHENYL)ACETOHYDRAZIDE
• Synonyms: 2-(3,5-DIFLUOROPHENYL)ACETIC ACID HYDRAZIDE;2-(3,5-DIFLUOROPHENYL)ACETOHYDRAZIDE
• CAS NO: 797784-29-3
• Molecular Formula: C₈H₈F₂N₂O
• Molecular Weight: 186.16
• Mol File: 797784-29-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 347.2 °C at 760 mmHg
• Flash Point: 163.8 °C
• Appearance: /
• Density: 1.327 g/cm³
• Vapor Pressure: 5.48E-05mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3,5-DIFLUOROPHENYL)ACETOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-DIFLUOROPHENYL)ACETOHYDRAZIDE(797784-29-3)
• EPA Substance Registry System: 2-(3,5-DIFLUOROPHENYL)ACETOHYDRAZIDE(797784-29-3)

Safety Data

• Hazardous Substances Data: 797784-29-3(Hazardous Substances Data)

Usage

General Description

2-(3,5-Difluorophenyl)acetohydrazide, also known as 2-(3,5-Difluorophenyl)hydrazinecarboxamide, is a chemical compound with the molecular formula C8H8F2N2O. It is a hydrazide derivative of 3,5-difluorophenylacetic acid and is commonly used in the synthesis of various pharmaceutical compounds. It is a white to off-white powder with a melting point of 165-167°C and is soluble in organic solvents such as dimethylformamide and chloroform. Its potential uses include its antimicrobial properties and potential applications in pharmaceutical research.

InChI:InChI=1/C8H8F2N2O/c9-6-1-5(2-7(10)4-6)3-8(13)12-11/h1-2,4H,3,11H2,(H,12,13)

Upstream product

• 105184-38-1 3,5-difluorophenyl acetic acid 
• 139368-37-9 ethyl 2-(3,5-difluorophenyl)acetate 
• 210530-70-4 methyl 2-(3,5-difluorophenyl)acetate 

Relevant articles and documents

Pyrrolidone derivative

The present invention relates to a pyrrolidone derivative and a pharmaceutically acceptable composition thereof, which are useful as inhibitors of methionine aminopeptidase.

MrgprX2 ANTAGONISTS AND USES THEREOF

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pha

A novel serine racemase inhibitor suppresses neuronal over-activation in vivo

Serine racemase (SRR) is an enzyme that produces D-serine from L-serine. D-Serine acts as an endogenous coagonist of NMDA-type glutamate receptors (NMDARs), which regulate many physiological functions. Over-activation of NMDARs induces excitotoxicity, which is observed in many neurodegenerative disorders and epilepsy states. In our previous works on the generation of SRR gene knockout (Srr-KO) mice and its protective effects against NMDA- and Aβ peptide-induced neurodegeneration, we hypothesized that the regulation of NMDARs’ over-activation by inhibition of SRR activity is one such therapeutic strategy to combat these disease states. In the previous study, we performed in silico screening to identify four compounds with inhibitory activities against recombinant SRR. Here, we synthesized 21 derivatives of candidate 1, one of four hit compounds, and performed screening by in vitro evaluations. The derivative 13J showed a significantly lower IC50 value in vitro, and suppressed neuronal over-activation in vivo.